Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Status:
Completed
Trial end date:
2018-07-17
Target enrollment:
Participant gender:
Summary
Multicenter Prospective Phase II Study for Neoadjuvant S-1 and Concurrent Radiotherapy for
Borderline Resectable Pancreatic Cancer
RATIONALE: Borderline resectable pancreatic cancer is frequently related to a positive
surgical margin and has a poor prognosis after resection. Neoadjuvant chemoradiation with
intensive local effect may lead to substantial local control and prolongation of survival in
borderline resectable pancreatic cancer.
PURPOSE: This phase II trial assess efficacy and safety of neoadjuvant S-1 and concurrent
radiotherapy for borderline resectable pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Japan Adjuvant Study Group of Pancreatic Cancer
Collaborators:
Japan Agency for Medical Research and Development Pharma Valley Center